Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 11/20 | 1.00 |
| ▸ | JAK3 | P52333 | 12/20 | 0.68 |
| ▸ | JAK2 | O60674 | 10/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 9/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21044810 | 0.92 | JAK1 (1.00) | JAK1JAK3JAK2PTK2 | |
| SCHEMBL21044831 | 0.91 | JAK1 (1.00) | JAK1JAK3JAK2PTK2 | |
| SCHEMBL19823053 | 0.89 | JAK1 (0.80) | JAK1JAK3JAK2PTK2 | |
| SCHEMBL19823050 | 0.88 | JAK1 (1.00) | JAK1JAK3JAK2PTK2 | |
| SCHEMBL21078397 | 0.86 | JAK1 (0.76) | JAK1JAK3JAK2PTK2 | |
| SCHEMBL19823063 | 0.86 | JAK1 (0.76) | JAK1JAK3JAK2PTK2 | |
| SCHEMBL24062643 | 0.84 | JAK1 (0.75) | JAK1JAK3JAK2PTK2 | |
| SCHEMBL21044840 | 0.81 | JAK1 (1.00) | JAK1JAK3JAK2PTK2 | |
| SCHEMBL21044824 | 0.80 | JAK1 (1.00) | JAK1JAK3JAK2PTK2 | |
| SCHEMBL21044823 | 0.79 | JAK1 (0.84) | JAK1JAK3JAK2PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | SUZHOU LONGBIOTECH PHARMACEUTICALS CO., LTD. (CN) | 2022-03-22 | — | — | US | disclosed |
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | JAK1, JAK2, JAK3 | JAK1 1/4885JAK3 3/4885JAK2 2/4885 |
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | JAK1, JAK2, JAK3 | JAK1 1/4885JAK3 3/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.